Synthego, a pioneering leader in genome engineering solutions, today announced that the Supreme Court of the United States has denied a petition for a writ of certiorari from Agilent Technologies, Inc ...

CRISPR Cas9 gene therapy explained with DNA scissors, hereditary diseases treatment, and designer babies ethical dilemmas ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $49.51, demonstrating a +1.43% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Crispr Therapeutics AG looks set for 2026 revenue inflection as Casgevy ramps; strong efficacy, undervalued shares, robust ...

Trace the timeline of CRISPR-Cas9 from its 2012 discovery to the latest AI-driven advancements and "N-of-1" clinical ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

CRISPR gene editing is a genetic technique that removes mutated genes and replaces them with nonmutated ones. While some research indicates it may help with vision, there is no conclusive evidence.

CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an ...